Claims
- 1. The compound, ((3-(2-amino-1,2-dioxoethyl)-1-((1,1′-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid morpholino-N-ethyl ester.
- 2. A pharmaceutical formulation comprising the compound of claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.
- 3. A method of inhibiting sPLA2 mediated release of fatty acid which comprises contacting sPLA2 with an therapeutically effective amount of the compound as claimed in claim 1.
- 4. The method of claim 3 wherein the contacting sPLA2 is done by oral administration of the compound as claimed in claim 1.
- 5. A method of treating a mammal to alleviate the pathological effects of septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, isteoarthritis, gout, spondylarthropathris, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enterapathric spondylitis, juvenile arthropathy, juvenile ankylosing spondylitis, reactive arthropathy, infectious or post-infectious arthritis, gonoccocal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with “vasculitic syndromes”, polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgin rheumatica, joint cell arteritis, calcium crystal deposition arthropathris, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, surcoilosis, hemochromatosis, sickle cell disease and other hemoglobinopathries, hyperlipo proteineimia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythrematosis, hemophilia, relapsing polychondritis, and cystic fibrosis; wherein the method comprises administration to said mammal a therapeutically effective amount of the compound as claimed in claim 1.
Parent Case Info
This application is a 371 of PCT/US 98/22679 filed Oct. 26, 1998, which claims benefit of Provisional application 60/063,646, filed Oct. 27, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US98/22679 |
|
WO |
00 |
3/29/2000 |
3/29/2000 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO99/21559 |
5/6/1999 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5654326 |
Bach et al. |
Aug 1997 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO9842343 |
Oct 1998 |
WO |
WO9921559 |
May 1999 |
WO |
WO 9925339 |
May 1999 |
WO |
Non-Patent Literature Citations (1)
Entry |
Lipsky, James J., The Lancet, vol. 348, pp. 1357-1359, Nov. 16, 1996. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/063646 |
Oct 1997 |
US |